Spike Protein News and Research

RSS

Soluble ACE2 level correlates with COVID-19 outcomes

Researchers at the Aarhus University, Denmark, found that high baseline levels of ACE2 in plasma from COVID-19 patients are tied to a worse outcome in hospitalized patients. The study, which appeared on the pre-print server medRxiv, shows that measuring ACE2 levels in serum can help determine patients at a higher risk of developing severe illness from SARS-CoV-2 infection.

14 Mar 2021

Study maps crucial component of long-term immune response to SARS-CoV-2

Researchers in the United States have found that protective antibodies generated against the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)– the agent that causes coronavirus disease 2019 (COVID-19) – also protect against viral variants.

14 Mar 2021

Cannabis compound inhibits SARS-CoV-2 replication in human lung cells

Researchers in the United States have conducted a study showing that a cannabis plant compound inhibited infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human lung cells.

14 Mar 2021

Neutralizing antibodies induced by COVID-19 vaccines less effective against new variants

SARS-CoV-2, the virus that causes COVID-19, has mutated throughout the pandemic. New variants of the virus have arisen throughout the world, including variants that might possess increased ability to spread or evade the immune system.

13 Mar 2021

An overview of the BNT162b2 COVID-19 vaccine by Pfizer-BioNTech

In a study published in the journal Drugs, a researcher tackled the approval of Pfizer-BioNTech’s COVID-19 vaccine, which has now been used in many countries.

12 Mar 2021

Study identifies three novel binding receptors for SARS-CoV-2

A team of scientists from the United Kingdom recently conducted a large-scale screening of several membrane-bound and soluble host cell receptors to identify novel binding partners for SARS-CoV-2. They have identified three novel receptors expressed on the human cell membrane; of which, one binds to SARS-CoV-2 spike with similar affinity as angiotensin-converting enzyme 2 (ACE2).

12 Mar 2021

Antibodies to SARS-CoV-2 spike protein and RBD detected in saliva of mRNA-vaccine recipients

A team of researchers from the US and the Netherlands recently reported that antibodies to the spike protein and the RBD are detected in saliva samples from healthcare workers vaccinated with mRNA vaccines.

12 Mar 2021

Spike protein mutations in SARS-CoV-2 variants help resist antibody neutralization

Researchers based in Beijing and Shenzhen, China, report that they have identified mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may allow variant strains to avoid neutralization by monoclonal antibodies and convalescent blood plasma.

11 Mar 2021

N501Y mutation in SARS-CoV-2 responsible for increased viral transmission

Researchers at the University of Texas, USA, have confirmed the specific mutation in the B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has allowed for it to be more transmissible than the ancestral strain. The N501Y substitution is one of 8 spike protein substitutions present in the UK variant and has also appeared convergently in the Brazil (P.1) and South Africa (B.1.351) variants.

11 Mar 2021

Structure and function of locked conformation of the SARS-CoV-2 spike protein identified

A new preprint research paper, posted to the bioRxiv* server, uncovered more information on the different structural conformations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The findings suggest the spike protein turns into a locked state to stabilize the spike protein during virus egress.

11 Mar 2021

Delaying second dose of Pfizer-BioNTech SARS-CoV-2 vaccine may be feasible in some cases

Researchers in Spain have conducted the most extensive study to date investigating the effectiveness of vaccinating healthcare workers with a single dose of the Pfizer-BioNTech vaccine to protect against coronavirus disease 2019 (COVID-19).

11 Mar 2021

Study addresses glycosylation concerns in SARS-CoV-2 vaccine design

An international team of researchers has found that glycosylation patterns are conserved across the native spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – and the recombinant spike proteins made in laboratories for use in vaccines.

11 Mar 2021

People previously infected with SARS-CoV-2 may achieve immunity after one mRNA vaccine dose, finds study

A team of researchers led by Thomas W. McDade of Northwestern University suggests people who were previously infected with SARS-CoV-2, the causative agent of COVID-19, may require only one dose of the mRNA vaccine to obtain immunity.

11 Mar 2021

Is a single mRNA COVID-19 vaccine dose enough for recovered individuals?

A new study deals with the evaluation of adaptive immune response to COVID-19 vaccination in candidates who have recovered from SARS-CoV-2 infection.

11 Mar 2021

SARS-CoV-2 spike S1 subunit induces hypercoagulability

The vascular complications of the condition include a range of various coagulopathies that cause bleeding and thrombocytopenia or a hypercoagulable state. A new preprint research paper posted to the medRxiv server describes the role of a fibrinogen-related protein in inducing these clinical features of COVID-19.

10 Mar 2021

Newly-discovered bat coronavirus 94.5% identical to SARS-CoV-2

Researchers in China and Australia have reported the discovery of novel bat coronaviruses that further reveal the diversity and complex evolutionary history of these viruses.

10 Mar 2021

Genome-wide covariation analysis sheds light on the evolution of SARS-CoV-2

Researchers in the United States have computed genome-wide covariation within severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to investigate interactions that could be of considerable importance in the prevention, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).

10 Mar 2021

Researcher find an emergent SARS-CoV-2 variant in California

Researchers have found a new SARS-CoV-2 variant in California, USA. This variant is more transmissible than circulating strains but slightly less transmissible than the new N501Y variant and moderately resistant to antibodies in convalescent sera and mRNA vaccines.

10 Mar 2021

Researchers characterize antibody responses to COVID-19 mRNA-based vaccine

A team of scientists from the USA and Canada has recently characterized the antibodies developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in response to an mRNA-based coronavirus disease 2019 (COVID-19) vaccine.

10 Mar 2021

Researchers study prevalence of SARS-CoV-2 UK variant at University of Texas

Researchers at the University of Texas at Austin and Santa Fe Institute in the US used quantitative polymerase chain reaction (PCR) data from a surveillance testing program on a large university campus to estimate how fast the new variant spreads. The team used the data to provide local situational information on the COVID-19 pandemic.

10 Mar 2021